Fate Therapeutics, Inc.
NASDAQ:FATEBiotechnology
-$0.00 today
- Market cap
- $122.39M
- Beta
- 2.52
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.08
Volume 1.87M
Average 2.92M
FATE EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Fate Therapeutics, Inc.NASDAQ: FATE
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.26, compared with -$0.32 a year earlier. Trailing-twelve-month EPS (Diluted) was -$1.09.
Context
- EPS (Diluted) grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 7 analysts of -$1.02 (+11.1%) for the fiscal year ending Dec 2026, a slowdown from the +29.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.26+3.7% QoQ
- Last fiscal yearDec 2025
- -$1.15+29.9% YoY
- LTMMar 2026
- -$1.09+26.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +18.8% | +7.8% | -10.9 pp |
| 1 year | +29.9% | +11.1% | -18.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (1.15) USD
- Year-over-year change
- +29.9%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.15) | +29.9% |
| FY2024 | 2024-12-31 | (1.64) | +0.0% |
| FY2023 | 2023-12-31 | (1.64) | +43.6% |
| FY2022 | 2022-12-31 | (2.91) | -29.9% |
| FY2021 | 2021-12-31 | (2.24) | — |
EPS (Diluted) vs competitors
How FATE compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +26.8% is the 4th highest of 10, against a peer median of +9.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$1.06 USD | +37.3% | — | |
| LTM Mar 2026 | -$1.09 USD | +26.8% | — | |
| LTM Mar 2026 | -$1.19 USD | +6.4% | — | |
| LTM Mar 2026 | -$1.34 USD | +11.3% | — | |
| LTM Mar 2026 | -CHF 1.56 CHF | +9.3% | — | |
| LTM Mar 2026 | -$1.71 USD | +99.9% | — | |
| LTM Mar 2026 | -$1.87 USD | +3.6% | — | |
| LTM Mar 2026 | -$2.1 USD | +32.9% | — | |
| LTM Mar 2026 | -$6.6 USD | +3.9% | — | |
| LTM Mar 2026 | -$838.86 USD | -2659.4% | — | |
| Peer median (excluding FATE) | — | +9.3% | — | |
Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.85M | 96.3M | 63.53M | 13.63M | 6.65M |
| Cost of Revenue | 5.85M | 13.76M | 157.19M | 118.53M | 12.9M |
| Gross Profit | 50M | 82.54M | (93.65M) | (104.9M) | (6.26M) |
| Gross Margin | 89.5% | 85.7% | -147.4% | -769.6% | -94.1% |
| Research & Development | 215.52M | 320.45M | 172.6M | 135M | 107.83M |
| Selling, General & Admin | 57.32M | 84.23M | 96.86M | 90.64M | 46.52M |
| Operating Expenses | 266.99M | 390.93M | 96.86M | 105.38M | 141.45M |
| Depreciation & Amortization | 5.85M | 13.76M | 18.28M | 18.96M | 9.3M |
| EBITDA | (206.3M) | (267.96M) | (142.65M) | (176.58M) | (127.02M) |
| EBITDA Margin | -369.4% | -278.3% | -224.5% | -1295.4% | -1911.2% |
| Operating Income | (216.99M) | (308.39M) | (190.51M) | (210.28M) | (147.7M) |
| Operating Margin | -388.6% | -320.2% | -299.9% | -1542.6% | -2222.4% |
| Interest Income | 1.31M | 5.84M | 17.19M | 17.29M | 11.05M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.84M | 26.67M | 29.58M | 24.01M | 11.39M |
| Income Before Tax | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Pre-Tax Margin | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (212.15M) | (281.72M) | (160.93M) | (186.26M) | (136.32M) |
| Net Margin | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| EPS (Basic) | (2.24) | (2.91) | (1.64) | (1.64) | (1.15) |
| EPS (Diluted) | (2.24) | (2.91) | (1.64) | (1.64) | (1.15) |
| Weighted Avg Shares | 94.75M | 96.83M | 98.41M | 113.69M | 118.79M |
| Weighted Avg Shares (Diluted) | 94.75M | 96.83M | 98.41M | 113.69M | 118.79M |
Fate Therapeutics, Inc.
NASDAQ:FATE
Intrinsic Alpha fair value
Locked
Current Price
$1.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.